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Increased levels of both the cysteine protease, cathepsin L, and the serinc protease, uPA (urokinase-typc lasminogen activator), are present in 
solid tumors and are correlated with malignancy, uPA is released by tumor cells as an inactive single.chain proenzyme (pro-uPA) which has to 
be activated by proteolytic cleavage. We analyzed in detail the action of the cysteine protcase, cathepsin L, on recombinant human pro-uPA. 
Enzymatic assays, SDS-PAGE and Western blot analysis revealed that cathepsin L is a potent activator of pro.uPA, As determined by N-terminal 
amino acid sequence analysis, activation of pro-uPA by cathepsin L is achieved by cleavage of the Lys~K-lle~9 peptidc bond, a common activation 
site of serine proteases such as plasmin and kallikrcin. Similar to cathepsin B (Kobayashi et al,, J. Biol, Chem, (1991) 266, 5147-5152) cleavage 
of pro-uPA by cathepsin L was most efl'~ctive atacidic pH (molar atio ofcathepsin L to pro-uPA of 1:2,000), Nevertheless, even at pH 7,0, pro-uPA 
was activated by cathepsin L, althougla 10-fold higher concentration f cathep~in L was required, As tumor cells may produce both pro-uPA 
and cathepsin L, implications for the activation of tumor cell-derived pro-uPA by cathepsin L may be considered. Different pathways of activation 
of pro-uPA in tumor tissues may coexist: (i) autoeatalytic intrinsic activation of pro-uPA; (it) activation by serine protcases (plhsmin, kallikrein, 
Factor Xlla); and (iii) activation by cysteine proteases (cathepsin B and L), 
Pro-uPA; Urokiuase: Cysteine protease; Cathepsin B; Cathepsin L; N-Terminal amino acid sequence analysis 
1. INTRODUCTION 
Elevated levels of proteases are present in solid 
tumors of the breast, ovary, colon, stomach, prostate 
and lung [1-8]. Collagenases, cathepsins, plasmin and 
plasminogen activators are found at various locations; 
in the cytoplasma, on the cell surface or released into 
the extracellular space [8-10]. These proteases not only 
degrade tissue components and constituents of the ex- 
tracellular matrix but also activate proenzymes and thus 
help to support umor cell invasion and metastases [11]. 
An enzymatically inactive proenzyme form of the 
urokinase.type plasminogen activator (pro-uPA) is 
secreted by stroma cells and by tumor cells [8,12]. Pro- 
uPA binds to high affinity receptors located on the 
tumor cell surface and is then converted into the en- 
zymaticall2¢ active two-chain form of uPA (HMW-uPA) 
by the proteases plasmin, kallikrein or eathepsin B [13- 
Abbreviations: BSA, bovine serum albumin; GFD, growth factor-like 
domain; E-64, t rans-epoxysuceinyl-L-leueylamino-(guanidiao)- 
butane; HPLC, high-performance liquid chromatography; HMW- 
uPA, high molecular weight form of uPA; mAb, monoelonal anti- 
body; pro-uPA, proenzyme form of uPA (enzymatically inactive); 
ttPA, urokinase-type lasminogen activator, 
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16]. Tumor cell invasion and metastasis i a complex 
multistep rocess which ultimately depends on the net 
balance of various biochemical properties of the tumor 
cell (e.g. protease activity, growth factors, steroid 
hormones, immunogenicity, cell adhesion, attachmeat 
factors). Elevated levels of the cysteine proteases, ca- 
thepsin B, L and uPA, have been correlated with in- 
creased malignancy [3,4,5,8,17-22]. This may be due to 
the fact that cysteine proteases efficiently convert 
soluble or tumor cell receptor-bound pro-uPA to cat- 
alytically active two-chain HMW-uPA [16]. Increased 
content of uPA in tumor tissues of the breast even al- 
lows to discriminate between those patients having a 
low or a high risk to eventually develop metastases 
[4,5,21,22]. We now report that in addition to cathepsin 
B, another potent lysosomal cysteine protease, ca- 
thepsin L, also cleaves pro-uPA with high efficiency to 
render catalytically active HMW-uPA. 
2. MATERIALS AND METHODS 
2,1. Materials 
Purified human eath~psin L (EC 3,4.22.15; Mr = 28,000; 208/~8/ml) 
and cathepsin B (EC 3.4.22.1; Mr = 28,000; 400 ,ug/ml) were obtained 
from Medor (Herrsehing/M~nchen, Germany), Haman cathepsin L
was purified by the manufacturer according to the method escribed 
in [42,43]. E.64, an inhibitor of eathepsin B and L, and human plasmia 
were from Sigma (Manchen, Germany). Recombinant human pro- 
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uPA (Saruplase) expressed in Eschertchia col( was donated by 
Grthaenthal (Stolberg, Germany). Naturally occurring glycosylated 
HMW-uPA (Ukidan) purified from human urlne was from Serene 
(Freiburg, Germany). The chromogenie substrate pyro-Glu-Gly.Arg- 
pNA was purchased from Bachcm Biochemica (Heidelberg, 
Germany), and aprotinin (Antagosan) was from Behrin$.Werke 
(Marburg, Germany), 
2.2, Methods 
2.2.1, Digestion of pro-uPA by cathepsin B and L or plasmin 
Pro-uPA was incubated with increasing concentrations ofcathepsin 
B, L or plasmin, respectively (75 rain, 37°C), For digestion, pro.uPA 
was dissolved at pH 4.5 and 7,0, respectively, in 15 mM sodium 
phosphate buffer containing 1.5 mM F.DTA and 2.5 mM cystein¢. 
Digestion of pro-uPA with plasmin was performed in 0. I M Tris.HCl 
containing 50 mM NaCI, pH 7.0. Reactions with cathepsin B and L, 
resp~tlvely, were terminated by the addition of E-64 (final concentra- 
tion of 10 pM), Digestion of pro-uPA with plasmin was stopped by 
tile addition of 50 k,l,U, aprotinin/ml, Samples were assayed for uPA 
enzymatic activity (at 405 nm) towards the synthetic substrate pyre. 
Glu-Gly-Arg-pNA in 50 mM Tris-HCl containing 40 mM NaCI, pH 
8.8, uPA activity was calculated in Ploug units, Actlve-slte titration of 
eathepsin L has not been performed. Samples (5-10.ug of protein per 
lane) were also separated by SDS-PAGE (15% acrylamid¢) according 
to Laemmli [23] in a Mini-Protean il apparatus (Bio-Rad), Selected 
samples were electrophoretically transferred to a fiuorotrans 
membrane (0.2/~m; Pall, Dreieich, Germany). The membrane was 
blocked with 2% BSA in 20 mM Tris-HCl containing 0.125 M NaCI, 
pH 7,5 (TBS). The membrane was i,lcubated with mAb #3471 (Amer- 
ican Diagnostica, Greenwich, N J), specific for a peptide sequenex 
within the growth factor.like domain of uPA (uPA~7_s.~), asdescribed 
[16], Molecular weight markers (in kDa) used (Bio-Rad) were phos. 
phorylase b (97,4), BSA (66,2), ovalbumin (45,0). carbonic anhydrase 
(31,0), soybean trypsin inhibitor (21,5) and lysozyme (14.4). 
2,2,2, Reverse-phase HPLC and N-terminal amino acid sequence 
analysis 
1 mg pro-uPA was incubated with 1 pg cathepsin L (pH 4.5, 37°C, 
1 and 2 h, respectively) and also at pH 7,0 (4 h, 37°C), For another 
experiment, 1 mg pro-uPA was digested with 0, I/w~ cathepsin L at pH 
4.5 (4 h, 37°C) in the buffer described above, Reduction of disulfide 
bonds was achieved by boiling (2 rain) of the digested pro-uPA in 6 
M guanidine hydrochloride (Merck, Darmstadt, Germany), 3% (v/v) 
2-mercapto=thanol, 10 mM Tris-HCi, pH B,5 and pyridylethylated 
with 4,5% (v/v) 4-vinylp},ridine (23°C, 1,5 h; Fluka AG. Bachs, Switz. 
erland) and then the reaction was stopped by adjusting the pH of the 
buffer to 2,0-3.0 with HCI, The peptides were separated on a 
Pharmaeia-LKB HPLC system equipped with a Pep-S/C-18 column 
(Pharmacia-LKB) ol~rating at 23°C with a flow rate of 1.0 ml/min. 
The column was equilibrated with 0.1% trifluoroaeetie acid in H:O. 
Elution of peptides was achieved by a linear gradient of 10-50% 
ac~tonitrile/0.1% triftuoroacetic acid within 60 mln, N-Terminal 
amino acid sequence analysis was performed with a gas phase se- 
quencer (470 A Protein Sequencer, Applied Biosystems) following the 
manufacturer's in tructions, Each peptide sample was submitted to 8 
Edman degradation cycles, 
3. RESULTS AND DISCUSSION 
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Fig, 1. Proteolytic activation of pro-uPA by cathepsin B, L or plasmin. 
(A) Dose-dependent activation of pro-uPA (1 me/roll by cathepsin L 
at pH 4,5 (e) or pH 7.0 (&) (75 rain, 37°C) was assayed by measuring 
the amidolytic activity of uPA towards pyro-Glu-Gly-Arg-pNA. (B) 
Dose-dependent activation of pro-uPA (I mg/ml) by eathepsin B (~) 
and cathepsin L (el at pH 4.5, and b), plasmin (11) at pH 7,0175 rain, 
37°C), (C) Time-dependent activation of pro-uPA by cathepsin L at 
pH 4.5 (el and pH 7.0 (&), and by plasmin at pH 7.0 (11) at a molar 
ratio of protea~e to pro-uPA of 1:1,600. At indicated time points 
aliquots were removed for enzymatic assays. The reaction was ter- 
minated by E-64 (cathepsin L) and aprotinin (plasmin), respectively. 
Conditions were as described in Fig. IA. 
3.1, Cleavage of pro-uPA by cathepsin L yields en- 
zymatically active HM W-uPA 
Both pro -uPA and cathepsin L are generated by 
human tumor  celI~ and released into the extracellular 
space [8,10,24,25]. In intracellular lysosomes cathepsin 
L exerts its max imum catalytic capacity at acidic pH, 
similar to eathepsin B [26]. To  investigate the proteoly-  
tic action of  cathepsin L on pro-uPA,  recombinant  pro-  
uPA was therefore incubated with various concentra-  
t ions o f  purified cathepsin L at pH 4.5 (Fig. IA).  Evi- 
dently, cathepsin L activates pro -uPA with high ef- 
ficiency. Max imum activation was achieved at a molar  
ratio o f  cathepsin L to pro -uPA o f  1:2.090 to i:7,000. 
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Fig. 2. SDS-PAGE analysis of cleavage of pro-uPA by cathcpsin L. 
The SDS-PAGE (reducing conditinna) displays the dose-dependent 
clcavagc of pro-uPA (I mgfml) by cathepsin L at (A) pH 4.5 and (B) 
pH 7.0, at various molar ratios of cathepsin L to pro-uPA (75 min, 
37°C): (lane 1) 48,000; (lane 2) 24,000; (lane 3) 16,000; (lane 4) 8,000; 
(lane 5) 1,600; (lane 6) 800; (lane 7) 400; (lane 8) 200; (lane 9) 100. 
Marker proteins are indicated in kDa. Please, note that the molecular 
weight of the B-chain of urinary MMW-uPA (Ukidan) which was used 
as a reference protein is slightly higher than that of recombinant 
pro-uPA due to glycosylation. 
The activation of pro-uPA at pH 4.5, however, is only 
transient and depends on the ratio of cathepsin L to 
pro-uPA. At higher concentrations of cathepsin L irre- 
versible degradation of both the A- and B-chain of uPA 
occurs (Fig. 2A). Activation of pro-uPA by cathepsin 
L takes also place at pH 7.0 (Figs. 1A and 2B). In 
contrast o pH 4.5, activation requires a higher dose of 
cathepsin L at neutral pH (molar ratio of cathepsin L
to pro-uPA of 1:200). Under this condition optimum 
activation of pro-uPA but no degradation of the A- and 
B-chain of uPA was observed (Fig. 2B). No activation 
of pro-uPA by cathepsin L was observed at alkaline pH 
(3pH g.0). Activation of pro-uPA by cathepsin L (pH 
4.5) is as efficient as activation by plasmin (pH 7.0) (Fig. 
1B). Optimum activation of pro-uPA by cathepsin B 
(pH 4.5) requires a relatively high concentration of ca- 
thepsin B; the course of activation parallels that of ca- 
thcpsin L at pH 7.0 (Fig. 1A). Time-dependent activa- 
tion of pro-uPA by cathepsin L (pH 4.5 and 7.0) and by 
plasmin (pH 7.0) are depicted at a molar ratio of pro- 
tease to pro-uPA of 1: 1,600 (Fig. 1C); maximum activa- 
tion of pro-uPA was achieved within I h by plasmin and 
by cathepsin L at pH 4.5. 
To demonstrate the specificity of cathepsin L action 
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FiB. 3. Cleuvage of pro-uPA by cathepsin L is inhibited by the cystcine 
protease inhibitor E-64 but not by the serinc protcasc inhibitor apro- 
tinin. As demonstrated bySDS-PAGE, cleavage of pro-uPA is caused 
by the cysteine proteasc athepsin L and is not due to t~ntaminating 
serine proteases. This is evident by the fact that tbc cystcinc protcase 
inhibitor E-64 completely prevented pro-uPA activation whereas the 
serine proteasc inhibitor aprotinin was without ci%ct. Activation 
strictly dcpcndcd on the presence of a rcduciny agent (c.g. cysteinc). 
A molar ratio of protease to pro-uPA of I: 1.600 was applied (60 min, 
37°C). The pH value for cathcpsin L digestion was 4.5; for plasmin 
digestion 7.0. (Lane I) pro-uPA in the presence of Plasmin, then 
addition of aprotinin; (lane 2) pro-uPA in the presence of cathepsin 
L, no cystcinc added; (lane 3) pro-uPA in the presence of cathcpsin 
L, cysteinc and sprotinin; (lane 4) pro-uPA in the presence of ca- 
tbcpsin L, cystcinc, aprotinin and E-64; (lane 5) pro-uPA in the pres- 
ence of catbepsin L, cystcine and E-64. 
on pro-uPA several control experiments (SDS-PAGE) 
were carried out (Fig. 3). Pro-uPA was incubated with 
cathepsin L in the presence or absence of the thiol 
reagent cysteine, the cysteine protease inhibitor E-64 
and the serine protease inhibitor aprotinin, respectively. 
Cleavage of pro-uPA by cathepsin L at pH 4.5 requires 
a reducing agent such as cysteine; cleavage is prevented 
by E-64. Cathepsin L action on pro-uPA is not affected 
by aprotinin indicating that trace contaminations of 
cdthepsin L with serine proteases are not responsible for 
the cleavage of pro-uPA. Similar results were obtained 
at pH 7.0. No cleavage of pro-uPA by cathepsin L was 
observed at alkaline pH (X%0). As reported by the 
authors [la], treatment of pro-uPA with cathepsin D 
does not lead to significant activation of pro-uPA, 
therefore possible trace contaminations of the cathepsin 
L preparation with the aspartic protease cathepsin D 
are negligible. Prior to SDS-PAGE, aliquots of the 
samples were subjected to determination of amidolytic 
activity in order to confirm the SDS-PAGE results (data 
not shown). The loss of amidolytic activity of uPA at 
pH 4.5 at high concentration of cathepsin L is due to 
the high proteolytic potential of cathepsin L. Published 
data characterize cathepsin L as a very potent lysosomal 
endopeptidase [27-29-J. Cathepsin B is a less active en- 
dopeptidase although the amino acid sequences of both 
cathepsins B and L clearly show that they have evolved 
from a common ancestor [3&3ij. There are two other 
lysosomal cysteine proteases known, cathepsin H and 
S, which are closely related to the cathepsins B and L 
[443. Cathepsin S also degrades a variety of protein 
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Table I 
Identification of cathepsin L cleavage sites In pro-UPA by N-terminal amino acid sequence 
analysis 
HPLC - fraction N-terminal amino acid sequence Component CotI 
Al 
39 
G’lG Q H C E I D K 
44 
E&lDKSKTC ‘I’ 
A-chain 
A-chain 
A2 
Bl 
82 
Cl 
c2 
c3 
c4 
159 
K&I IGGEFTT B-chain 
1 
SNELHQVP 
6 
HkVPSNCDC 
A-chain 
A-chain 
159 
K-jl I G G E FT ‘I 
162 
B-chain 
G-k E F ‘T T I E N B-chain 
6 
H*QVPSNCDC 
60 
RJGKASTDtM 
A-chain 
A-chain 
394 
SJH F 1 P W I R S 
391 
TJ.RVSHFLPW 
B-chain 
B-chain 
6 
H&QVPSNCDC 
1 
SNELHQVP 
A-chain 
A-chain 
162 
G&GEFTTIEN 
1456 
TLT I E N Q P W F ’ 
159 
K&I I GGEFTT 
B-chain 
B-chain 
B-chain 
& denotes the cathepsin L cleavage site; major sequences are shown In bold face; ihe 
positlon of the first residue is Indicated. 
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Fig. 4, Western blot analysis of pro-uPA cleavage by cathepsin L or 
plasmin. Pro-aPA was treated with cathepsin L at pH 4,5 (60 rain, ~ 0, 6 
37°C; lanes 4 and 5) or pH 7,0 (lanes 9 and 3) or with plasmln at pH = Qj  
7,0 (lane 1), The samples were subjected to SDS.PAOE and electro- 
transfer as described in Materials and Methods, The transttuoro- ~ 0,~ 
membrane was blocked with 2% BSA and then incubated with mAb ..c:l 
#M,71, which is directed to the receptor binding domain within the t . .  
0.2 growth factor-like domain of uPA [16], Note that only intact pro-uPA m 
and the A-chain(s), but not the B.chain, of uPA were stained, The '~  
molar ratios of protease to pro-uPA were a~ follows: (lane 1) h2,500; '~  0. 0 
(lane 2) 1:8,000; (lane 3) 1:1,600; (lane 4) 1:8,000; (lane 5) 1:400. 
substrates, including collagen with a high specific activ- 
ity, and is considered to play an important role in in- 
tracellular protein breakdown [45--4.7]. The two cysteine 
proteases, cathepsin B and L, seem likely to account for 
most of the contribution of this group of enzymes to 
physiological and pathophysiological proteolysis 
[32,33]. 
Pro-uPA which has been activated by cathepsin L
(HMW-uPA) still binds to uPA receptors on tumor cells 
indicating an intact binding domain within GFD of 
HMW-uPA. Binding of active HMW-uPA to tumor cell 
receptors was confirmed by flow cytofluorometry 
[16,41]. HMW-uPA effectively competed for binding of 
fluorescent FITC-pro-uPA to receptors on U-937 cells 
(data not shown). Unimpaired GFD can also be demon- 
strated (Western blot analysis) by use of mAB #3471 
which is directed to the peptide sequence 17-32 within 
GFD representing the receptor binding domain (Fig. 4). 
MAb #3471 only recognizes intact uPAtT_32 within pro- 
uPA and the A-chain of HMW-uPA [16], and does not 
react with the B-chain of HMW-uPA [16]. 
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3.2. Cleavage of pro.uPA by cathepsht L occurs between 
Lys lss and lie is9 
N-Terminal amino acid sequence determination was 
applied in order to identify the exact position(s) of the 
cleavage site(s) in cathepsin L-treated pro-uPA (Table 
I). pro-uPA was treated with cathepsin L at pH 7.0 
(molar ratio of cathepsin L to pro-uPA of i:i,600) and 
pH 4.5 (molar ratio of eathepsin L to pro-uPA of 
1:16,000), respectively, and then, alter reduction and 
alkylation, the resulting uPA polypeptides were sep- 
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Fig. 5. Reverse-phase HPLC ofpro-uPA cleaved by cathepsin L. uPA 
fragments derived from pro-uPA by digestion with cathepsin L were 
analyzed by reverse-phase HPLC, 500,ag of digested uPA peptides 
were separated, The numbered peaks were collected and submitted to 
N-terminal amino acid sequence determination, The N.terminal se- 
quences (B steps) of polypeptides contained in these peaks are given 
in Table 1. (A) 4 h, 370C, pH 7,0, Molar ratio of cathepsin L to 
pro-uPA of 1:1,600. (B) 4 h, 37°C, pH 4,5, Molar ratio of cathepsin 
L to pro-uPA of 1:16.000, (C) 2 h, 370C, pH 4,5. Molar ratio of 
cathepsin L to pro-uPA of 1:1,600. 
arated by reverse-phase HPLC (Fig. 5A,B). At a higher 
concentration of cathepsin L (molar ratio of cathepsin 
L to pro-uPA of l:l,600; pH 4.5) degradation of both 
the A- and the B-chain of uPA occurred (Fig. 5C). This 
is in agreement with the SDS-PAGE pattern depicted in 
Fig. 2. The major peaks were collected and then sub- 
jected to N.terminal amino acid sequence analysis. The 
A-chaln polypeptide eluted first (31-33% acetonitrile), 
followed by the B-chain (40-42% acetonitrile) (Fig. 
5A,B). 
On  the basis of the known sequence of pro-uPA 
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[34,35], identification of major and minor cleavage sites 
was ensured (Table I). The major cleavage site is be- 
tween Lys15* and Ile’59. This is the common activation 
site known for the serinr proteases plasmin, kalfikr& 
and trypsin [I 51 but also for the cysteine protease ca- 
thepsin B [ IG]. Another important cleavage site (Gly’“‘- 
Gly’“‘) was detected when pro-uPA was treated with a 
high concentration of cathepsin L at pH 4.5 for 2 h 
(peak 4 in Fig. SC). The resulting HMW-uPA was en- 
zymatically inactive and was found to contain a B-chain 
component (up to 80% of total) starting with the N- 
terminal sequence Gly-Glu-Phe-Thr-. In parallel, pro- 
uPA was incubated only for 1 h with cathepsin L under 
the same conditions as in Fig. 5C, the cleavage mixture 
was separated by reverse-phase HPLC without reduc- 
tion and was then assessed for the cleavage site(s). N- 
Terminal amino acid sequence analysis revealed the 
miijor activation site between Lys’5s-Ile’59, and a major 
cleavage site between Gly’6’-G1y’6z reflecting the tran- 
sitory activation of pro-uPA by cathepsin L at acidic 
pH. The A-chain was cleaved between His’-Gln’. 
Cathepsin L has a broad amino acid specificity 
[32,33]. The identified cleavage sites in cathepsin L- 
treated pro-uPA show that cathepsin L splits peptide 
bonds involving the carboxyl groups of glycine, lysine, 
threonine, serine, isoleucine, histidine, arginine or glu- 
tamic acid. The broad substrate specificity of cathepsin 
L has also been shown by other investigators. They 
demonstrated that cathepsin L is able to cleave the ex- 
tracellular matrix protein collagen [27,36]. Cathepsin L 
has even been described as a potent elastasc-like enzyme 
degrading elastin, another extracellular protein resis- 
tant to mo5t proteases [37]. 
Cathepsin L may even play an important role in cell 
growth and cell transformation as the major excreted 
protein (MEP) of transformed mouse fibroblasts has 
been reported recently to be identical with the precursor 
molecule of cathepsin L (procathepsin L) [38-40]. MEP 
is also secreted by untransformed mouse cells in res- 
ponse to tumor promoters or growth factors. There is 
published evidence that treatment of NIH 3T3 cells with 
platelet-derived growth factor will cause selective secre- 
tion of pro-cathepsin L; other lysosomal enzymes were 
not detected in the media from PDGF-treated cells [20]. 
The procathepsin L molecule has a small amount of 
latent activity which is stimulated at low pI-1 or by clea- 
vage with another proteinase such as cathepsin D 
[48,49]. Procathepsins l3 and L were detected in media 
from premalignant and malignant colon tumor cell lines 
in equal amounts, but only medium from malignant cell 
lines contained mature cathepsins B and L, which were 
active against an isolated basement membrane matrix 
in vitro [ 181. The finding of significant activity of mature 
CZtitiepStti L ;ir llctrrar p’r*, . -2 *.-et -U g;C the c*~idcace fcr euro. 
processing of procathepsin L to active cathepsin L at 
neutral pH in this work, argue for a possible role of 
cathepsin L in tumor invasiveness. Mature cathepsin L
is not stable for long periods at neutral pH [SO], yet we 
observed no autolysis at pH 7.0. It is possible that the 
presence of substrates can retard or prevent autolysis. 
It hss r,-tin:ly been reported that the pH optimum of 
recombinant mature cathepsin L is higher than that 
published for human liver cathepsin L: thus cathepsin 
L preparations from different sources can possess activ- 
ity at various p1-l profiles [50,51]. Our finding, namely 
the effective activation of pro-uPA by cathepsin L, may 
also be of importance for tumor spread and metastasis 
as uPA has been shown to be an important prognostic 
factor for increased relapse formation and shorter over- 
all survival in breast cancer patients [4,5,21,22]. Sofar, 
detailed clinical studies on the interaction of cysteine 
proteases and pro-uPA/uPA levels in cancer patients 
and the outcome of the disease have not been reported. 
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